Compounds > s 2337
Page last updated: 2024-12-08

s 2337

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S 2337: synthetic substrate used to estimate Factor X [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID194257
MeSH IDM0097780

Synonyms (9)

Synonym
s 2337
67608-06-4
piperidin-1-yl (4s)-4-amino-5-[[2-[[(2s,3s)-2-benzamido-3-methylpentanoyl]-[(2s)-5-(diaminomethylideneamino)-2-(4-nitroanilino)pentanoyl]amino]-2-oxoethyl]amino]-5-oxopentanoate
s-2337 ,
bz-ile-glu(gamma-piperidyl)-gly-arg-pna
l-argininamide, n-benzoyl-l-isoleucyl-5-oxo-5-(1-piperidinyl)-l-norvalylglycyl-n-(4-nitrophenyl)-
l-argininamide, n-benzoyl-l-isoleucyl-5-oxo-5-(1-piperidinyloxy)-l-norvalylglycyl-n-(4-nitrophenyl)-
DTXSID30986969
n-(1-{[({2-amino-1-hydroxy-5-oxo-5-[(piperidin-1-yl)oxy]pentylidene}amino)acetyl][5-carbamimidamido-2-(4-nitroanilino)pentanoyl]amino}-3-methyl-1-oxopentan-2-yl)benzenecarboximidic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (75.00)18.7374
1990's2 (25.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
h-d-phe-pip-arg-pna
S 2238: chromogenic substrate for thrombin; used in amidolytic assay; patterned after N-terminal portion of A alpha chain of fibrinogen; synonym S-2238 refers to di-HCl		1.9810
dermatan sulfate
Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.		1.9810amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
n(alpha)-phosphorylalanylproline
N(alpha)-phosphorylalanylproline: inhibitor of angiotensin converting enzyme; RN given refers to (L)-isomer		1.9810
benzoyl-ile-glu-gly-arg-p-nitroanilide
benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide: p-nitroanilide deriv of portion of peptide sequence in prothrombin molecule cleaved by Factor X		1.9610
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Liver Dysfunction
[description not available]		01.9610
Liver Diseases
Pathological processes of the LIVER.		01.9610
Deficiency, Factor 10
[description not available]		01.9610
Factor X Deficiency
Blood coagulation disorder usually inherited as an autosomal recessive trait, though it can be acquired. It is characterized by defective activity in both the intrinsic and extrinsic pathways, impaired thromboplastin time, and impaired prothrombin consumption.		01.9610
Thrombocytopathy
[description not available]		01.9810
Symptom Cluster
[description not available]		01.9810
Blood Platelet Disorders
Disorders caused by abnormalities in platelet count or function.		01.9810
Syndrome
A characteristic symptom complex.		01.9810
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9810